What is BPC-157 and where does it come from?

BPC-157 (Body Protective Compound-157) is a synthetic pentadecapeptide — a fifteen-amino-acid sequence — derived from a protein naturally found in human gastric juice. It was identified and isolated during research into endogenous gastric peptides with cytoprotective properties. BPC-157 is not found in food and is not a naturally occurring circulating peptide; it is synthesized as a research compound. It is not FDA-approved and is currently under review for its 503A compounding classification ahead of the July 2026 FDA PCAC meeting.

What tissue repair properties has BPC-157 demonstrated in preclinical research?

Preclinical research has documented BPC-157 activity across multiple tissue-repair mechanisms: it promotes angiogenesis (new blood vessel formation) by upregulating VEGF and stimulating endothelial cell migration; it activates fibroblast proliferation and collagen synthesis relevant to tendon and musculoskeletal repair; it modulates nitric oxide (NO) signaling to reduce inflammation; and it exhibits gastrointestinal cytoprotection in rodent models of mucosal injury. These effects have been observed across a range of animal models, including studies of tendon rupture, bone fracture, GI fistula, and neurological injury. Human clinical data remains limited to small pilot cohorts.

Is BPC-157 legal to research in the United States?

BPC-157 is not an FDA-approved drug and is not scheduled as a controlled substance. It has historically been available for researcher and patient-specific use through 503A compounding pharmacies. Its current 503A classification is Category 2 — a regulatory holding position indicating prior PCAC review found insufficient evidence for positive listing, but no final prohibition has been issued. The July 2026 FDA PCAC meeting will re-evaluate this classification. Researchers sourcing BPC-157 through licensed 503A compounders are operating within the current regulatory framework, though that framework is under active review.

What Is BPC-157? A Research Overview

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from a partial sequence of human gastric juice protein, consisting of 15 amino acids. All information presented here is drawn from peer-reviewed preclinical and in vitro literature; this content is intended for research purposes only and does not constitute medical advice or guidance for human use.

Background and Molecular Identity

BPC-157 was isolated and characterized primarily through the work of Predrag Sikiric and colleagues at the University of Zagreb, whose laboratory has produced the majority of published research on this compound over the past three decades. The peptide sequence (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) is considered a partial sequence of the gastric juice protein BPC, designated "BPC" because the native protein was originally isolated from human gastric acid secretions.

Because BPC-157 does not occur freely in nature in its isolated 15-amino-acid form, it is classified as a synthetic research compound. Its stability in aqueous solution — relative to many other peptides — has made it a practical tool for in vivo rodent studies.

See the BPC-157 compound library entry for molecular data, sequence, and registry identifiers.

Proposed Mechanisms: EGR-1 and Transcription Factor Modulation

One of the central mechanistic proposals in BPC-157 research involves modulation of Early Growth Response Protein 1 (EGR-1), a zinc-finger transcription factor that regulates genes involved in tissue repair, cell growth, and angiogenesis. Sikiric et al. (2018, Current Pharmaceutical Design) proposed that BPC-157's cytoprotective effects may be partially mediated through EGR-1 upregulation, which in turn drives expression of downstream targets including growth factors involved in wound healing.

This mechanistic framing remains largely hypothetical in published literature — direct evidence from chromatin immunoprecipitation or promoter-reporter assays in human cell lines is limited. Most mechanistic data derives from rodent models or cell culture experiments.

NO System Interactions

Several publications from the Sikiric group have suggested interactions between BPC-157 and the nitric oxide (NO) system. Studies using L-NAME (an NOS inhibitor) and L-arginine in rodent models indicated that BPC-157's gastrointestinal protective effects could be partially attenuated or modulated by these agents, implying cross-talk with endothelial NO synthase (eNOS) pathways (Sikiric et al., Life Sciences, 2001). The precise molecular interaction points have not been fully elucidated.

VEGF and Angiogenesis Research

A notable body of preclinical work has examined BPC-157's apparent pro-angiogenic properties. Chang et al. (2014, Journal of Applied Physiology) reported increased VEGF expression in tendon fibroblast cultures treated with BPC-157, with associated increases in tubule formation in HUVEC assays. The authors proposed that VEGF upregulation may represent a primary mechanism by which the compound accelerates soft tissue healing in rodent injury models.

Hsieh et al. (2015, Phytomedicine) also reported accelerated wound closure and increased microvessel density in rat skin wound models, consistent with a pro-angiogenic activity profile. These findings are from animal models and have not been replicated in controlled human studies.

Tendon and Ligament Studies

The most replicated category of BPC-157 preclinical research involves musculoskeletal healing models. Staresinic et al. (2003, Journal of Orthopaedic Research) demonstrated significantly accelerated Achilles tendon healing in rats following transection, with histological assessment showing improved collagen fiber organization in BPC-157-treated animals compared to saline controls.

Subsequent studies examined medial collateral ligament transection models (Pevec et al., Journal of Orthopaedic Surgery and Research, 2010) and reported similar improvements in tensile strength recovery metrics. These animal-model findings are frequently cited in the secondary literature but have not progressed to human clinical trials as of the current literature review.

Bone Healing

A smaller set of studies has examined bone repair contexts. Augustin et al. (2014, Journal of Orthopaedic Research) reported improved segmental bone defect healing in rats treated with BPC-157, with densitometric and histomorphometric improvements over controls. The proposed mechanism involved enhanced osteoblast recruitment and periosteal vascularization.

Gastrointestinal Protective Effects

Sikiric's earliest work on BPC-157 was primarily framed around gastroprotection. Studies in rat models of NSAID-induced gastric ulceration (Sikiric et al., Journal of Physiology — Paris, 1997) reported significant reductions in lesion area with BPC-157 administration. Subsequent work extended these findings to models of inflammatory bowel disease (IBD), including TNBS-induced colitis (Veljaca et al., Journal of Pharmacology and Experimental Therapeutics, 1994).

The compound has also been studied in rodent models of short bowel syndrome and anastomotic healing, with Drmic et al. (2018, World Journal of Gastroenterology) reporting improved anastomotic bursting pressure and reduced inflammatory infiltration in treated animals.

Cytoprotection and Stress Models

Rosenfeld et al. and the broader Sikiric lab have published on BPC-157's apparent protective effects against stress-induced gastric lesions in rats, proposing that the compound may interact with dopaminergic and serotonergic pathways in the enteric nervous system. This body of work has accumulated primarily in Journal of Physiology — Paris and Current Pharmaceutical Design across multiple decades.

Key Sikiric Laboratory Publications

The bulk of published primary research on BPC-157 originates from a single research group. This concentration of authorship is a recognized limitation in the literature. Key publications include:

Sikiric, P. et al. (1993). "The influence of a novel pentadecapeptide, BPC 157, on N(G)-nitro-L-arginine methylester and L-arginine effects on stomach mucosa integrity and blood pressure in rats." European Journal of Pharmacology
Sikiric, P. et al. (2006). "Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease." Current Pharmaceutical Design
Sikiric, P. et al. (2018). "Brain-gut axis and pentadecapeptide BPC 157." Current Neuropharmacology
Chang, C.H. et al. (2011). "The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration." Journal of Applied Physiology

Research Limitations and Current Status

Despite a substantial volume of preclinical data, BPC-157 has not completed Phase II or Phase III human clinical trials for any indication as of 2025. Independent replication of key findings by groups unaffiliated with the Sikiric laboratory remains limited. The compound does not have regulatory approval from the FDA, EMA, or comparable agencies for any therapeutic use.

Researchers interested in this compound should consult the BPC-157 compound library entry for updated regulatory status, available assay formats, and literature links. All preclinical findings discussed here are from animal or in vitro models and cannot be extrapolated to human therapeutic outcomes.

See also: BPC-157 compound library entry

All content on ClinicalPeptide.org is intended for researchers and educators working in biochemistry, pharmacology, and related disciplines. Nothing on this site constitutes medical advice, and no information should be interpreted as guidance for human self-administration of any compound.